VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2020 | GO-FLAG: bridge therapy to allo-SCT in R/R AML

Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, reports on the use of the GO-FLAG regimen (gemtuzumab ozogamicin with fludarabine, cytarabine, and G-CSF), as a bridge therapy to allogeneic stem cell transplantation (allo-SCT) in relapsed/refractory (R/R) acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter